๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Uncoupling of p21WAF1/CIP1/SDI1 mRNA and protein expression upon genotoxic stress

โœ Scribed by Butz, Karin; Geisen, Caroline; Ullmann, Angela; Zentgraf, Hanswalter; Hoppe-Seyler, Felix


Book ID
110061482
Publisher
Nature Publishing Group
Year
1998
Tongue
English
Weight
404 KB
Volume
17
Category
Article
ISSN
0950-9232

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Regulation of cyclin-dependent kinase in
โœ J H Albrecht; A H Meyer; M Y Hu ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 817 KB

WAF1/Cip1/Sdi1 (p21) is the prototype of a family of proteins that inhibit cyclin-dependent kinases and regulate cell cycle progression in eukaryotic cells. In addition to normal cell cycle progression, p21 is involved in growth suppression mediated by p53 and transforming growth factor beta (TGFbet

Prognostic value and expression of p21(w
โœ Aaltomaa, S.; Lipponen, P.; Eskelinen, M.; Ala-Opas, M.; Kosma, V.M. ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 206 KB ๐Ÿ‘ 3 views

BACKGROUND. p21(waf1/cip1) protein is a cyclin-dependent kinase inhibitor able to arrest the cell cycle at the G1 phase by inhibiting DNA replication. The expression of p21(waf1/cip1) and its prognostic value in prostate cancer are largely unexplored. METHODS. We used immunohistochemistry to analyze

Expression of p21 (waf1/cip1/sdi1), but
โœ Yoshihito Gomyo; Mitsuyuki Ikeda; Mitsuhiko Osaki; Shigeru Tatebe; Shunichi Tsuj ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 167 KB ๐Ÿ‘ 1 views

## RESULTS. Various levels of p21 and p53 immunoreactivities in carcinoma cells were detected in 30 (32%) and 60 (65%), respectively, of 93 samples. There was no 1 First Department of Pathology, Faculty of Medcorrelation between p21 and p53 expression. The 5-year survival rate of patients icine, T

Multiple pathways control cell growth an
โœ Cox, Lynne S. ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 91 KB ๐Ÿ‘ 1 views

Many tumour therapies act by inducing a cellular damage response pathway mediated by the tumour suppressor protein p53. Alternative outcomes of p53 induction include apoptosis or transient cell-cycle arrest, both thought to require the transcriptional activity of wild-type p53. Current research high